

DAFTAR PUSTAKA

- Abdel-Misih, S.R.Z., Bloomston, M. 2010. *Liver Anatomy*. Surgical Clinics of North America. 90 (2010) 643–653. doi:10.1016/j.suc.2010.04.017
- Anis, M. (2011) '*Imaging of Hepatocellular Carcinoma: Practical Guide to Diffeerential Diagnosis*', liver.theclinics.com, 15, pp. 335–352. doi: 10.1016/j.cld.2011.03.014.
- Arslanoglu, A., Chalian, H., Sodagari, F., Seyal, A. R., Töre, H. G., Salem, R., & Yaghmai, V. (2016). *Threshold for enhancement in treated hepatocellular carcinoma on MDCT: Effect on necrosis quantification*. American Journal of Roentgenology, 206(3), 536–543. <https://doi.org/10.2214/ajr.15.15339>
- Arslanoglu, A., Seyal, A.R., Sodagari, F., Sahin, A., Miller, F.H., Salem, R., Yaghmai, V. 2016. *Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review*. American Journal of Roentgonology. 2016; 207:W1–W11. DOI:10.2214/AJR.15.15490
- Bernardi, M., Maggioli, C., Zaccherini, G. (2012). *Human albumin in the management of complications of liver cirrhosis*. Critical Care. 2012, 16:211. DOI: 10.1007/978-3-642-25716-2
- Bernardi, M., Ricci, C. and Zaccherini, G. (2014). *Role of Human Albumin in the Management of Complications of Liver Cirrhosis*. *Journal of Clinical and Experimental Hepatology*, 4(4), pp.302-311. doi:10.1186/cc11218
- Bruix, J. and Sherman, M. (2011) '*Management of hepatocellular carcinoma: An update*', *Hepatology*, 53(3), pp. 1020–1022. doi: 10.1002/hep.24199.
- Carr, B. I., & Guerra, V. (2013). *Hepatocellular Carcinoma Size: Platelets, γ -Glutamyl Transpeptidase, and Alkaline Phosphatase*. *Oncology*, 85(3), 153–159. doi:10.1159/000354416
- Carr, B. I., Guerra, V., & Pancoska, P. (2012). *Thrombocytopenia in Relation to Tumor Size in Patients with Hepatocellular Carcinoma*. *Oncology*, 83(6), 339–345. doi:10.1159/000342431

- Carr, B. I., Guerra, V., Giannini, E. G., Farinati, F., Ciccarese, F., ... Rapaccini, G. L. (2014). *Significance of Platelet and AFP Levels and Liver Function Parameters for HCC Size and Survival*. *The International Journal of Biological Markers*, 29(3), 215–223. doi:10.5301/jbm.5000064
- Chartampilas, E., Rafailidis, V., Georgopoulou, V., Kalarakis, G., Hatzidakis, A., & Prassopoulos, P. (2022). *Current imaging diagnosis of hepatocellular carcinoma*. *Cancers*, 14(16), 3997. <https://doi.org/10.3390/cancers14163997>
- Chernyak, V., Fowler, K. J., Kamaya, A., Kielar, A. Z., Elsayes, K. M., Bashir, M. R., Kono, Y., Do, R. K., Mitchell, D. G., Singal, A. G., Tang, A., & Sirlin, C. B. (2018). *Liver imaging reporting and data system (li-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients*. *Radiology*, 289(3), 816–830. <https://doi.org/10.1148/radiol.2018181494>
- Cholankeril, G., Patel, R., Khurana, S., & Satapathy, S. K. (2017). *Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management*. *World Journal of Hepatology*, 9(11), 533. doi:10.4254/wjh.v9.i11.533
- Ellis, H. 2011. *Anatomy of the liver*. *Surgery* : 29(12), pp. 589– 592. Elsevier Ltd. doi: 10.1016/j.mpsur.2011.09.012.
- Elsayes, K. M., Kielar, A. Z., Chernyak, V., Morshid, A., Furlan, A., Masch, W. R., Marks, R. M., Kamaya, A., Do, R. K. G., Kono, Y., Fowler, K. J., Tang, A., Bashir, M. R., Hecht, E. M., Jambhekar, K., Lyshchik, A., Rodgers, S. K., Heiken, J. P., Kohli, M., ... Sirlin, C. B. (2019). *Li-rads: A conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance*. *Journal of Hepatocellular Carcinoma*, Volume 6, 49–69. <https://doi.org/10.2147/jhc.s186239>
- El-Serag, H. B. and Rudolph, K. L. (2007) '*Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis*', *Gastroenterology*, 132(7), pp. 2557–2576. doi: 10.1053/j.gastro.2007.04.061.

- Farazi, P. A. and DePinho, R. A. (2006) '*Hepatocellular carcinoma pathogenesis: From genes to environment*', Nat Rev Cancer, 6(9), pp. 674–687. doi: 10.1038/nrc1934.
- Forner, A., Reig, M. and Bruix, J. (2018). *Hepatocellular carcinoma*. The Lancet, 391(10127), pp.1301-1314.
- Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A. and Pawlik, T. M. (2016) '*Hepatocellular carcinoma: From diagnosis to treatment*', Surgical Oncology. Elsevier Ltd, 25(2), pp. 74–85. doi: 10.1016/j.suronc.2016.03.002.
- Hennedige TP, Neo WT, Venkatesh SK. (2014) *Imaging of malignancies of the biliary tract- an update*. Cancer Imaging. Apr 22;14(1):14. doi: 10.1186/1470-7330-14-14. PMID: 25608662; PMCID: PMC4331820.
- Ho, S.Y., Liu, P.H., Hsu, C.Y., Hsia, C.Y., Lee, Y.H., Lee, R.C., *et al.* (2017). *Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization*. PLoS ONE. 12(7): e0180408. <https://doi.org/10.1371/journal.pone.0180408>.
- Hoekstra, L.T., de Graaf, W., Nibourg, G.A.A., Heger, M., Bennink, R.J., Stiegre, B., *et al.* (2013). *Physiological and Biochemical Basis of Clinical Liver Function Tests*. Annals of Surgery. 2013;257: 27–36. DOI: 10.1097/SLA.0b013e31825d5d47
- Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., *et al.* (2014). *Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade*. Journal Clinical of Oncology. 33:550-558. DOI: 10.1200/JCO.2014.57.9151
- Keng, V. W., Largaespada, D. A., & Villanueva, A. (2012). *Why men are at higher risk for hepatocellular carcinoma?* Journal of Hepatology, 57(2), 453–454. <https://doi.org/10.1016/j.jhep.2012.03.004>
- Kulik, L., El-Serag, H.B. (2019). *Epidemiology and Management of Hepatocellular Carcinoma*. Gastroenterology. 2019;:-1 –15.

- Kulkarni, N. M., Fung, A., Kambadakone, A. R., & Yeh, B. M. (2021). *Computed tomography techniques, protocols, advancements, and future directions in liver diseases. Magnetic Resonance Imaging Clinics of North America*, 29(3), 305–320. <https://doi.org/10.1016/j.mric.2021.05.002>
- Li, Z., Tuteja, G., Schug, J., & Kaestner, K. H. (2012). *FOXA1 and FOXA2 are essential for sexual dimorphism in liver cancer. Cell*, 148(1–2), 72–83. <https://doi.org/10.1016/j.cell.2011.11.026>
- Llovet, J.M., Lencioni, R. 2020. *mRECIST for HCC: Performance and novel refinements. Journal of Hepatology*. 2020 vol. 72 j 288–306
- Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016). *Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology*, 14(1). <https://doi.org/10.1016/j.cgh.2015.07.019>
- Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018). *Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology*, 68(2), 723–750. <https://doi.org/10.1002/hep.29913>
- McEvoy, S. H., McCarthy, C. J., Lavelle, L. P., Moran, D. E., Cantwell, C. P., Skehan, S. J., Gibney, R. G., & Malone, D. E. (2013). *Hepatocellular carcinoma: Illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the study of liver diseases. RadioGraphics*, 33(6), 1653–1668. <https://doi.org/10.1148/rg.336125104>
- Mossanen, J. C., & Tacke, F. (2013). *Role of lymphocytes in liver cancer. OncoImmunology*, 2(11). <https://doi.org/10.4161/onci.26468>
- Padhya, K. T., Marrero, J. A. and Singal, A. G. (2013) ‘Recent advances in the treatment of hepatocellular carcinoma’, *Curr Opin Gastroenterol*, 29(3), pp. 285–292. doi: 10.1097/MOG.0b013e32835ff1cf.

- Pradana, G. D. (2021). *Hubungan Antara RASIO trombosit-limfosit TERHADAP prognosis menggunakan Nottingham prognostic index Pada Penderita Kanker Payudara di RSUP Dr Sardjito*. Universitas Gadjah Mada. Retrieved May 5, 2023, from <http://etd.repository.ugm.ac.id/penelitian/detail/205479>
- Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J. (2022). *BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update*. *Journal of Hepatology*, 76(3), 681–693. <https://doi.org/10.1016/j.jhep.2021.11.018>
- Richani, M., Kolly, P., Knoepfli, M., Herrmann, E., Zweifel, M., Tengg-Kobligh, H. von, ... Dufour, J.-F. (2016). *Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm*. *Annals of Hepatology*, 15(1), 82–90. doi:10.5604/16652681.1184233
- Sanyal, A. J., Yoon, S. K. and Lencioni, R. (2010) ‘*The Etiology of Hepatocellular Carcinoma and Consequences for Treatment*’, *The Oncologist*, 15(Supplement 4), pp. 14–22. doi: 10.1634/theoncologist.2010-S4-14.
- Scheiner, B., Kirstein, M., Popp, S., Hucke, F., Bota, S., Rohr-Udilova, N., ... Pinter, M. (2018). *Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma*. *Liver Cancer*, 1–15. doi:10.1159/000489833
- Song, D.S. and Bae, S.H. (2012) “*Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period*,” *Clinical and Molecular Hepatology*, 18(3), p. 258. Available at: <https://doi.org/10.3350/cmh.2012.18.3.258>.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). *Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>

- Trefts, E., Gannon, M., & Wasserman, D. H. (2017). *The liver*. Current Biology, 27(21). <https://doi.org/10.1016/j.cub.2017.09.019>
- Villanueva, A. (2019) “*Hepatocellular carcinoma*,” New England Journal of Medicine, 380(15), pp. 1450–1462. Available at: <https://doi.org/10.1056/nejmra1713263>.
- Waller, L. P., Deshpande, V. and Pyrsopoulos, N. (2015) ‘*Hepatocellular carcinoma: A comprehensive review*’, World J Hepatol, 7(26), pp. 2648–2663. doi: 10.4254/wjh.v7.i26.2648.
- Willatt, J., Ruma, J. A., Azar, S. F., Dasika, N. L., & Syed, F. (2017). *Imaging of hepatocellular carcinoma and image guided therapies - how we do it*. Cancer Imaging, 17(1). <https://doi.org/10.1186/s40644-017-0110-z>
- Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A., Roberts, L.R. 2019. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nature reviews. Gastroenterology & Hepatology. <https://doi.org/10.1038/s41575-019-0186-1>
- Younossi, Z.M. and Henry, L. (2021) “*Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma*,” JHEP Reports, 3(4), p. 100305. Available at: <https://doi.org/10.1016/j.jhepr.2021.100305>.
- Zanetto, A., Campello, E., Spiezia, L., Burra, P., Simioni, P., & Russo, F. (2018). *Cancer-associated thrombosis in cirrhotic patients with hepatocellular carcinoma*. Cancers, 10(11), 450. <https://doi.org/10.3390/cancers10110450>
- Zhang, C., Cheng, Y., Zhang, S., Fan, J., & Gao, Q. (2022). *Changing epidemiology of hepatocellular carcinoma in Asia*. Liver International, 42(9), 2029–2041. <https://doi.org/10.1111/liv.15251>
- Zhao, C., Dai, H., Shao, J., He, Q., Su, W., Wang, P., Tang, Q., Zeng, J., Xu, S., Zhao, J., & Xiang, S. (2021). *Accuracy of various forms of contrast-enhanced MRI for diagnosing hepatocellular carcinoma: A systematic review and meta-analysis*. Frontiers in Oncology, 11. <https://doi.org/10.3389/fonc.2021.680691>